Trial Profile
A multicenter study of simeprevir, pegylated interferon plus ribavirin in patients with hepatitis C virus infection assessing impact of an inosine triphosphatase polymorphism on bilirubin increases
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Dec 2015
Price :
$35
*
At a glance
- Drugs Peginterferon (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics
- 28 Dec 2015 New trial record